Dose aims to improve lives affected by type 2 diabetes by offering personalized health services and non-invasive blood glucose measurements. It plans to acquire licenses, develop prototypes, and launch its product in the UK diabetes market, which it forecasts could generate sales of £9-22.5 million annually by 2021. Financial projections estimate Dose could be valued at £56.4 million based on anticipated revenue growth and profitability.

1. DOSE!

2. DOSE.DOSE
Monitor your glucose.

3. DOSE

5. THE DOSE TEAM

6. Dose aims to improve the lives of those affected by type 2 diabetes by offering
completely personalised health services and non-invasive blood glucose level
measurements.

7. DOSE
Free
Premium

8. TECHNOLOGY

9. DOSE
Key Players:
Diabetes patients
NHS
Government
Private Hospitals
Meet their
Needs:
Potential diabetics
IBM
UC San Diego
Media
Show
Consideration:
Novartis UK Ltd.
GlaxoSmithKline plc.
Astra Zeneca UK Ltd.
Least
Important:
General public

10. STRATEGY
Differentiation Licensing B2B

11. TIMELINE
-2
Acquire Licenses
Funding
-1
Prototype
Regulatory Approval
0
Launch
1
Business
Relation
Development
2
Product
Extension

12. MARKETING

13. RISK MANAGEMENT
Risks Assumptions Dependencies

14. FINANCES
0.00
50.00
100.00
150.00
200.00
250.00
300.00
350.00
400.00
450.00
2015 2016 2017 2018 2019 2020 2021
Relative Market Size (UK)
Market Size (GBP millions) Company Sales (GBP millions)
Market Share - 3% to 5.7%
Dose's Sales - 9m to 22.5m

15. 0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%
2016 2017 2018 2019 2020 2021
Relative Growth Rate (UK)
Company Growth Rate Market Growth Rate
Size effect narrows

16. 0.00
5.00
10.00
15.00
20.00
25.00
2015.5 2016 2016.5 2017 2017.5 2018 2018.5 2019 2019.5 2020 2020.5
Revenue Profit Free Cash Flow
Profit - 1.69m to 6.15m
Free Cash Flow - 0.22m to 5.7m
Profitability

17. Discounted Value (£m) 55.79
Adding Initial Cash (£m) 0.73
Firm Value (£m) 56.52
Subtracting Total Debt 0.13
Implied Equity Value (£m) 56.40
Valuation and Sensitivity
Sensitivity of Dose's Valuation to WACC and Long Term FCF Growth Rate
WACC
3% 4% 5% 6% 7% 8% 9% 10% 11% 12%
LongTermFCFGrowthRate
1% 79.63 52.17 38.47 30.27 24.82 20.93 18.03 15.79 13.99 12.54
2% 156.68 77.00 50.48 37.24 29.31 24.04 20.29 17.49 15.31 13.58
3% nmf 151.49 74.49 48.85 36.05 28.39 23.30 19.67 16.96 14.86
4% nmf nmf 146.52 72.08 47.29 34.92 27.51 22.59 19.08 16.46
5% nmf nmf nmf 141.76 69.77 45.80 33.83 26.67 21.90 18.51
6% nmf nmf nmf nmf 137.20 67.56 44.37 32.79 25.86 21.24
7% nmf nmf nmf nmf nmf 132.83 65.43 42.99 31.79 25.08
8% nmf nmf nmf nmf nmf nmf 128.63 63.39 41.67 30.82
9% nmf nmf nmf nmf nmf nmf nmf 124.60 61.44 40.40
10% nmf nmf nmf nmf nmf nmf nmf nmf 120.74 59.56

18. 0 1 2 3 4 5 6 7 8
2016
2018
2019
MILLIONS (GBP)
Private Market Equity Placement Venture Capital Bank Loan
Funding
Bank Loan - 1.96m
Venture Capital - 7.5m
Private Equity - 0.5m
Cumulative - 9.96m

19. £170,000

20. DOSE
Monitor your glucose.